| 10/15/2015 | CV | Market Commentary: FXCM slips; SanDisk mixed in active trade; Xilinx contracts; Amyris prices, older Amyris at 80
|
| 10/15/2015 | CV | Market Commentary: Morning Commentary: SanDisk remains mixed, active; Xilinx contracts; Amyris prices, older Amyris at 80
|
| 10/14/2015 | PP | Market Commentary: SanDisk mixed on takeout chatter; Cepheid contracts after warning; Amyris offering on tap
|
| 10/14/2015 | CV | Market Commentary: SanDisk mixed on takeout chatter; Cepheid contracts after warning; Amyris offering on tap
|
| 10/14/2015 | CV | Market Commentary: Morning Commentary: Cepheid comes in after revenue warning; Amyris plans $50 million convertibles
|
| 7/18/2014 | PP | Market Commentary: Cemex unchanged with earnings; Cepheid adds a little as shares slide; Spirit Capital stronger
|
| 7/18/2014 | CV | Market Commentary: Cemex unchanged with earnings; Cepheid adds a little as shares slide; Spirit Capital stronger
|
| 4/21/2014 | CV | Market Commentary: Convertibles quiet in post-holiday trade; SanDisk active, in line; SINA seen slipping
|
| 2/24/2014 | CV | Market Commentary: Midday Commentary: GT Advanced trades higher after earnings; Cepheid continues to trade
|
| 2/24/2014 | CV | Market Commentary: GT Advanced expands as shares surge on earnings; DryShips higher; Cepheid trades actively
|
| 2/10/2014 | CV | Cepheid greenshoe exercised, lifts 1.25% convertibles to $345 million
|
| 2/5/2014 | CV | Market Commentary: Midday Commentary: New Cepheid convertibles rise on debut; secondary market sees slow action
|
| 2/5/2014 | CV | Market Commentary: Cepheid convertibles add on debut; Fluidigm extends gains; secondary sees slow action
|
| 2/4/2014 | CV | Cepheid ups planned seven-year convertibles to $300 million, tightens talk to 1.25%-1.5%, up 32.5%
|
| 2/4/2014 | CV | Market Commentary: Midday Commentary: Herbalife prices at the cheaps, slips; Cepheid, American Energy on tap
|
| 2/4/2014 | CV | New Issue: Cepheid prices $300 million 1.25% seven-year convertibles, up 32.5%
|
| 2/4/2014 | CV | Market Commentary: Herbalife slips after pricing; Cepheid talk gets tightened; NRG, American Energy on tap
|
| 2/3/2014 | CV | Market Commentary: Convertibles weaken; Herbalife's planned $1 billion offering in focus; InterMune sinks
|
| 2/3/2014 | CV | Cepheid plans $250 million seven-year convertibles to yield 1.5%-2%, up 27.5%-32.5%
|
| 6/26/2007 | SS | Market Commentary: Huntsman pressures Lyondell, lifts KMG; Ventana pushes Cepheid; BCE off; Vonage up
|
| 8/30/2006 | BT | Cepheid gets funding for phase 2 study of assay to detect tuberculosis, drug resistance
|
| 8/22/2006 | BT | Cepheid Xpert GBS test categorized as 'moderate complexity'
|
| 7/26/2006 | BT | Cepheid to market Xpert GBS strep test
|
| 6/29/2006 | BT | Cepheid expands patent license to include HIV, hepatitis C
|
| 6/19/2006 | BT | Cepheid sells Xpert EV meningitis test in Europe
|
| 5/23/2006 | BT | Cepheid to develop rapid tuberculosis test for developing nations
|
| 4/17/2006 | BT | Cepheid submits Xpert EV assay for FDA approval
|
| 4/3/2006 | BT | Cepheid's Xpert GBS molecular testing system released in Europe
|
| 3/22/2006 | BT | Cepheid GeneXpert system receives Homeland Security certification
|
| 3/21/2006 | BT | Cepheid's new test delivers results for anthrax, bubonic plague, rabbit fever
|
| 3/8/2006 | BT | New Issue: Cepheid raises $86 million in follow-on of 10 million shares at $8.60 each
|
| 3/8/2006 | BT | Market Commentary: Alexza IPO gets off; Cepheid off; Dyax deal seen; Elan, Biogen up; Neurocrine shakes off trial miss
|
| 3/1/2006 | BT | Cepheid submits Xpert GBS test for use on the GeneXpert system for U.S. regulatory review
|
| 3/1/2006 | BT | Market Commentary: Cepheid follow-on on deck; Akorn bags $19.4 million; Novavax results priced in; Exubera buoys Nektar
|
| 2/24/2006 | BT | Cepheid plans follow-on offering of 10 million shares via UBS
|
| 2/24/2006 | BT | Market Commentary: Corautus, Cepheid deals emerge; BioMarin bounces; GCP gains on PIPEs deal; Par pounced on news
|
| 2/23/2006 | BT | Cepheid launches GeneXpert, Xpert BCR-ABL Monitor assay for in-vitro diagnostic use
|
| 2/3/2006 | BT | Cepheid files $120 million stock shelf
|
| 12/2/2005 | BT | Cepheid enters license agreement with DxS Ltd.
|
| 12/20/2001 | CVHY | Cepheid files $35 million debt, preferred, stock, warrants shelf
|
